Endo bets up to $221M on NuPathe and its migraine patch

Endo Health Solutions ($ENDP) is extending its makeover with a bolt-on deal, trading $105 million up front for NuPathe ($PATH) to get its hands on the migraine patch Zecuity. Under the deal, Endo will fork over another $79 million if the patch's sales cross $100 million a year and another $37 million if they clear $300 million. NuPathe won FDA approval for Zecuity in January, and Endo said it plans to launch the sumatriptan-delivering patch in the first half of next year. The deal comes a month after Endo announced its plans to spend $1.6 billion for Canada's Paladin Labs, kicking off its effort to refocus on specialty pharmaceuticals. More